Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 4Breast 3Genitourinary 2Sarcoma 1Gastrointestinal 1Dermatologic 1Classical hematology 1

Conditions

Ovarian Neoplasms 1Neoplastic Syndromes, Hereditary 1Hematologic Neoplasms 1Fanconi Anemia, Complementation Group D1 1Cytopenia 1Congenital Bone Marrow Failure Syndromes 1Breast Neoplasms 1Bone Marrow Failure Disorders 1

Interventions

olaparib 5stinging nettle lectin 1peppermint oil 1niraparib 1liposomal doxorubicin 1ferrous fumarate 1apixaban 1angiotensin I (1-7) 1Tretinoin 1Trabectedin 1Surveys and Questionnaires 1Rivaroxaban 1Pharmacokinetics 1Heparin, Low-Molecular-Weight 1Genetic Counseling 1Gemcitabine 1Ferric Oxide, Saccharated 1Epoetin Alfa 1Demography 1Data Collection 1Darbepoetin alfa 1Counseling 1Cognitive Behavioral Therapy 1Carboplatin 1Aspirin 1Anticoagulants 1ALT-836 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Genetic Counseling × Classical hematology × Clear all
NCT00165152 2012-08-09

Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing

Dana-Farber Cancer Institute

Phase NA Completed
150 enrolled
BreastClassical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡